In this episode we chat with neurologist Dr Cassie Nesbitt, one of the principal investigators for haematopoietic stem cell transplantation (HSCT) at the Alfred Hospital in Melbourne. 

Cassie explains the process of HSCT, risks and considerations for accessing HSCT treatment overseas, as well as the current research on who is likely to benefit and how this is accessed in Australia. Cassie outlines things to consider when undergoing HSCT such as fertility preservation, and the impact of HSCT on the immune system. We chat about how hope plays a role in people taking risks for treatment, and the future of HSCT and treatment for MS. Cassie also highlights how collaborative the MS HSCT community of neurologists are, and that they welcome people who have undergone HSCT overseas to continue seeing their neurologists and engaging in their healthcare 

With thanks to Dr Cassie Nesbitt

Dr Cassie Nesbitt is a neurologist at Alfred Health in Melbourne. She is one of the principle investigators for HSCT at the Alfred, and one of the Autologous Haematopoietic Stem Cell Transplant (AHSCT) Registry Steering Committee Members.

You can read the episode transcript Here

For more information about HSCT:
MS Research Australia: https://www.msaustralia.org.au/ahsct/
Get in touch with MS Plus to speak with a Nurse Advisor about HSCT and treatment options

Reach out for support:
MS Plus Connect 1800 042 138 or email [email protected]

Get in touch to share your comments and suggestions about this episode, or for future guests and episode topics by emailing [email protected]

Views expressed on the MS Podcast, including any discussions or reference to medications or treatments by podcast guests, do not necessarily represent the views of MS Plus and should not be seen as either an endorsement or rejection of a treatment.  

MS Plus does not recommend any specific treatment for people living with MS. Decisions about any treatments, taking into consideration the potential benefits and side effects for each individual’s circumstances, should be made in careful consultation with the person’s neurologist or health care professional.